- Home
- UBFO vs PLX Comparison
UBFO vs PLX Comparison
Compare UBFO & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBFO
- PLX
- Stock Information
- Founded
- UBFO 1987
- PLX 1993
- Country
- UBFO United States
- PLX United States
- Employees
- UBFO N/A
- PLX N/A
- Industry
- UBFO Major Banks
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UBFO Finance
- PLX Health Care
- Exchange
- UBFO Nasdaq
- PLX Nasdaq
- Market Cap
- UBFO 162.0M
- PLX 160.2M
- IPO Year
- UBFO N/A
- PLX 1998
- Fundamental
- Price
- UBFO $8.64
- PLX $1.55
- Analyst Decision
- UBFO
- PLX Strong Buy
- Analyst Count
- UBFO 0
- PLX 1
- Target Price
- UBFO N/A
- PLX $15.00
- AVG Volume (30 Days)
- UBFO 23.4K
- PLX 1.4M
- Earning Date
- UBFO 07-17-2025
- PLX 05-09-2025
- Dividend Yield
- UBFO 5.56%
- PLX N/A
- EPS Growth
- UBFO N/A
- PLX N/A
- EPS
- UBFO 0.77
- PLX 0.05
- Revenue
- UBFO $47,362,000.00
- PLX $59,764,000.00
- Revenue This Year
- UBFO N/A
- PLX $65.02
- Revenue Next Year
- UBFO N/A
- PLX $57.34
- P/E Ratio
- UBFO $11.17
- PLX $32.18
- Revenue Growth
- UBFO N/A
- PLX 0.18
- 52 Week Low
- UBFO $7.07
- PLX $0.82
- 52 Week High
- UBFO $10.49
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- UBFO 44.97
- PLX 30.03
- Support Level
- UBFO $8.44
- PLX $1.54
- Resistance Level
- UBFO $8.69
- PLX $1.79
- Average True Range (ATR)
- UBFO 0.28
- PLX 0.11
- MACD
- UBFO -0.06
- PLX -0.02
- Stochastic Oscillator
- UBFO 18.87
- PLX 27.27
About UBFO United Security Bancshares
United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.